Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis, Insomnia
A Digital Therapeutic to Improve Insomnia in Multiple Sclerosis: A Randomized Controlled Trial.
The goal of this randomized controlled trial is to test the effectiveness of digital cognitive behavioral therapy for insomnia (dCBT-I) compared with digital patient education about insomnia for people with Multiple Sclerosis…
- Trial name
- NorseMS (NCT06113666)
- Testing
- Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I), Digital patient education about insomnia (PE)
- Where
- Norway
- Volunteers
- 550 people
- Sponsor
- St. Olavs Hospital
Relapsing Remitting Multiple Sclerosis
Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis
A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in patients treated with Copaxone for at least 3 months
- Trial name
- NCT00429442
- Testing
- Simvastatin
- Where
- Denmark
- Sponsor
- Anna Tsakiri
Relapsing Remitting Multiple Sclerosis
Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis
This research sub-study is being completed as a part of the Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects…
- Trial name
- NCT01337427
- Testing
- BIIB017
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Relapsing-Remitting
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
The study will evaluate the effectiveness and safety of the investigational drug SB683699 in treating patients with relapsing multiple sclerosis (MS), using data from magnetic resonance imaging (MRI) scans as the main measure.
- Trial name
- NCT00097331
- Testing
- SB683699
- Where
- 11 sites in Belgium, Germany and 3 more
- Volunteers
- 261 people
- Sponsor
- GlaxoSmithKline
Relapsing Remitting Multiple Sclerosis
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
The main purpose of this study is to assess the usability and value of the multiple sclerosis (MS) care management platform in terms of improved monitoring of people with MS (pwMS) in clinical practice.
- Trial name
- ILLUMINATE (NCT05949580)
- Testing
- MS Care Platform (icobrain ms and icompanion ms)
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Sclerosis
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
We aim to assess the effect of Ofatumumab on microglial activation using [F-18]PBR06 PET in MS patients in relation to changes in serum markers, MRI abnormalities and clinical impairment longitudinally over 9 months.
- Trial name
- NCT04510220
- Testing
- Ofatumumab, [F-18]PBR06
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Brigham and Women's Hospital
COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis)
Psilocybin Therapy for Psychological Distress in Palliative Patients
The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), Major Depressive Disorder (MDD)
- Trial name
- PsyPal (NCT06782724)
- Testing
- Psilocybin therapy
- Where
- 4 sites in Czechia, Denmark and 2 more
- Volunteers
- 108 people
- Sponsor
- University Medical Center Groningen
Multiple Sclerosis
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
This study evaluates the effect of adding fish oil to Fingolimod on some serum cytokines in patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- NCT02939079
- Testing
- Fingolimod, Fish Oil
- Volunteers
- 50 people
- Sponsor
- Isfahan University of Medical Sciences
Multiple Sclerosis
Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)
This study investigates whether there is a link between disease activity/progression in patients receiving Gilenya and expression of a putative biomarker signature in patients with multiple sclerosis.
- Trial name
- MS (NCT02408380)
- Where
- Canada
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- McGill University
Multiple Sclerosis, Relapsing-Remitting
A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
The study will assess the patients' satisfaction of treatment after 12 months treatment with fingolimod It also will assess the tolerability profile of fingolimod in a small population.
- Trial name
- NCT01578330
- Testing
- Fingolimod
- Where
- 11 sites in Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
Multiple sclerosis (MS) is an immune-mediated disease characterized primarily by inflammatory demyelinating lesions in the central nervous system (CNS), with the white matter being predominantly affected.
- Trial name
- NCT07353216
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Multiple Sclerosis
Dalfampridine in Egyptian Patients With Multiple Sclerosis
The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively…
- Trial name
- NCT05730738
- Testing
- Dalfampridine ER, 10 Mg Oral Tablet, Extended Release
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Multiple Sclerosis
Therapy Optimization in Multiple Sclerosis (MS)
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
- Trial name
- TOP MS (NCT00819000)
- Testing
- Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
- Where
- 3 sites in United States
- Volunteers
- 2,878 people
- Sponsor
- Teva Neuroscience, Inc.
Multiple Sclerosis
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone…
- Trial name
- CONFIDENCE (NCT02499900)
- Testing
- Copaxone®
- Where
- 97 sites in United States, Argentina and 14 more
- Volunteers
- 861 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis
Vitamin D3 supplementation reduces the incidence of multiple sclerosis.Although clinical cross-sectional studies have demonstrated vitamin D3 as a positive mediator in preventing relapses and disease progression, prospective…
- Trial name
- NCT01753375
- Testing
- Vitamin D3
- Where
- Saudi Arabia
- Volunteers
- 200 people
- Sponsor
- AlJohara M AlQuaiz, M.D.
Multiple Sclerosis, Relapsing-remitting
A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina
This is an observational, non-controlled, multicentric, prospective study planned to be conducted in 66 subjects diagnosed with multiple sclerosis (MS) in 20 centres of Argentina.
- Trial name
- NCT01080001
- Where
- Argentina
- Volunteers
- 71 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Pathologic Processes
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.
- Conditions
- Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases
- Trial name
- NCT03562975
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of South Florida
Anxiety
Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis
It is a multicentric randomized and controlled study comparing a Scheme therapy program versus local practice in RRMS patients with anxiety.
- Trial name
- NCT04030819
- Testing
- schema therapy
- Where
- France
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Paris Nanterre University
Multiple Sclerosis
Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS
The purpose of this study is to learn about the pharmacokinetics and pharmacodynamics of RPC1063 in RMS.
- Trial name
- NCT02797015
- Testing
- RPC1063
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Celgene
Primary Progressive Multiple Sclerosis
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
This Phase 2 study is intended to serve as a proof of concept for potential treatment with laquinimod in patients with PPMS. The study is also aimed at evaluating 2 doses of laquinimod in this population.
- Trial name
- ARPEGGIO (NCT02284568)
- Testing
- Laquinimod
- Where
- 99 sites in United States, Canada and 8 more
- Volunteers
- 374 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.